Objective       To compare the therapeutic effects between drugs and focused ultrasound in treatment of perennial allergic rhinitis (PAR).       Methods       A total of 284 cases of identified PAR who treated in our hospital during March 2009 to March 2011 were randomized divided into 2 matched groups

test group (n=140) and control group (n=144). Those of test group were treated by a CZB ultrasound therapeutic system [developed and produced by Chongqing Haifu (HIFU) Technology Co. Ltd.] to scan inferior nasal concha and the anterosuperior part of nasal septum under nasal endoscopy. While those of control group received a conventional drug treatment. The therapeutic effect were evaluated by clinical symptoms controlled counting- scores. Nasal endoscopic images were collected and comparatively observed before and at 1

6 and 12 months after the therapy of focus ultrasound.       Results       The symptom of nasal itching

rhinorrhea and sneezing in the test group was obviously relieved

while no nasoseptal perforation or nasal adhesion was found. The counting-scores was 11.15±2.54 before treatment and 4.68±1.25 after treatment in 1 year after the treatment in test group (P0.01). That was 12.09±2.11 before treatment and 7.12±1.31 in 1 year after treatment in the control group (P0.01). The follow-up data indicated the efficient rate in 1 month was 97.1% in test group

and 94.4% in control group (P0.01)

in 6 months was 90.7% and 85.4% respectively (P0.01)

and in 1 year was 80.7% and 61.1% respectively (P0.01).       Conclusion       The treatment of focus ultrasound in PAR is minimally invasive and safe with reliable efficacy.